Voritrol 200 mg Tablet 4s

Uses of Voritrol 200 mg Tablet 4s

Voriconazole is an antifungal medicine. Voriconazole uses include treatment of serious, invasive fungal infections.

Side Effects of Voritrol 200 mg Tablet 4s

Transient and reversible visual disturbances; fever; headache; abdominal pain; chills; asthenia; back pains; chest pain; face oedema; flu-like syndrome; hypotension; thrombophloebitis; phloebitis; GI disturbances (eg, nausea, vomiting, diarrhoea); jaundice; cheilitis; cholestatic jaundice; gastroenteritis; blood dyscrasias; purpura; peripheral oedema; facial oedema; hypokalaemia; hypoglycaemia; dizziness; hallucinations; confusion; depression; anxiety; tremor; agitation; paraesthesia; respiratory distress syndrome; sinusitis; rash; pruritus; photosensitivity; alopecia; exfoliative dermatitis; acute kidney failure; haematuria; infusion-related reactions. Increased LFT and serum creatinine; prolongation of QT interval. Potentially Fatal: Stevens-Johnson Syndrome, toxic epidermal necrolysis.

Drug Interactions

Increased INR with acenocoumarol and warfarin. Increased alfentanil, erlotinib, bosentan, sulphonylureas, ciclosporin, tacrolimus, benzodiazepines, and omeprazole levels. Increased risk of rhabdomyolysis with statins. Increased both delavirdine and voriconazole levels with concurrent use. Increased both HIV protease inhibitors and voriconazole levels with concurrent use. Decreased voriconazole levels and increased efavirenz levels with concurrent use. Increased risk of methadone toxicity with voriconazole. Reduced both phenytoin and voriconazole levels with concurrent use. Increased risk of neurotoxicity with vinca alkaloids. Decreased voriconazole and increased rifabutin levels with concurrent use. Avoid concurrent use with clopidogrel. Potentially Fatal: Increased risk of torsade de pointes with cisapride, astemizole, pimozide, quinidine and terfenadine. Reduced voriconazole levels with carbamazepine, rifampicin, ritonavir and phenobarbital. Increased risk of ergotism with ergot alkaloids. Increased sirolimus levels with voriconazole.

Contraindications

Hypersensitivity. Lactation.

Mechanism of Action

Voriconazole is a triazole antifungal agent which inhibits cytochrome P450-dependent enzymes thereby inhibiting ergosterol synthesis in fungal cell membranes. It has a broad spectrum of activity against all Candida species (including strains resistant to fluconazole) ,Aspergillus spp., Scedosporium spp., and Fusarium spp. Absorption: Rapidly and completely absorbed from GI tract. Bioavailability: 96% (oral). Peak plasma concentration: 1-2 hr. Food decreases oral absorption. Distribution: Protein binding: 58%; diffuses into CSF. Metabolism: Saturable metabolism. Metabolised by P450 isoenzyme CYP2C19, CYP2C9 and CYP3A4 to inactive metabolites. Excretion: Excreted in urine (80%).

Special Precautions

Monitor renal and hepatic function before and during treatment. Monitor visual function if used >28 days. Monitor pancreatic function in patients at risk of acute pancreatitis. Haematological malignancy; patients with proarrhythmic conditions; hepatic and renal impairment. Use in pregnancy not recommended, ensure effective contraception during treatment. Avoid exposure to sunlight. Correct electrolyte abnormalities before treatment initiation. May affect ability to drive or operate machinery and do not drive at nght.

How to Use

Take orally with food and water, as directed by your physician.

How to Store

Keep in a cool, dry place away from sunlight and moisture.

Safety Concerns

• Alcohol: Avoid during treatment.
• Breastfeeding: Not recommended.
• Pregnancy: Contraindicated.
• Liver/Kidney: Use with caution.

Content Disclaimer

This content is for educational purposes only. Please consult your doctor before use.